Exclusive: Harvard geneticist George Church knew more about Jeffrey Epstein's activities than he has previously said, before accepting new donations from the sex offender.

Back at JPM Element teased that they would be coming out with the VITARI, a benchtop sequencer capable of generating whole genomes for $100. This would best Illumina’s list price of $200 with the N…

Back at JPM Element teased that they would be coming out with the VITARI, a benchtop sequencer capable of generating whole genomes for $100. This would best Illumina’s list price of $200 with the N…

MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of sel...

I had been meaning to read the AlphaGenome paper on non-coding variant effect prediction from Google DeepMind which recently showed up in N...

A personal reflection on the life, legacy, and controversies of DNA co-discoverer James Watson, following his death at age 97.

An exclusive interview with Serge Saxonov of 10x Genomics and Giovanna Prout of Scale Biosciences on what the acquisition means for single cell genomics.

Element Biosciences today announced that installations of its flagship AVITI24 5D Multiomic system have surpassed 50 units globally.

The California startup will have to convince companies across the economy to swap from rolls of magnetic tape to DNA as the vessel for their most important digital data.

Or, a Colossal Pile of Bullshit

The AI unicorn's Perturb-seq atlas is publicly available and detects dose-dependent genetic effects to enhance predictive power for drug discovery.

For Illumina, its former employees are both a boon and a problem. In the 27 years since its founding, the DNA sequencing company unlocked new frontiers in biology, medicine and ...

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline launches.

The SEC is expected to drop an investigation into Illumina's $8 billion acquisition of cancer test developer Grail, Endpoints News has learned.

Novartis plans to make San Diego the center of its West Coast research hub.

China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.

Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four hours, potentially a major step forward for an industry that’s vital for diag...

After 10+ years of mostly silence, Roche is finally starting to lift the curtain on their nanopore sequencer. It’s based on a combination of Genia’s nanopore platform (acquired in 2014) and Stratos…

Illumina announces a new NGS-based spatial technology kit and new software platform, Illumina Connected Multiomics.

Is Roche going to "knock it out of the park" or "jump the shark"? Everyone I know is excited, even if many of them are sceptical, about the Feb 20th webinar and what we will learn about SBX. Alex Dick...

It’s been an exciting couple of years for the sequencing market. Unless you’re a sequencing company, especially one named “Illumina”, and then maybe it’s been more terrifying. But for sequencing cu…

YouTube video by xkcd's What If?

GROWdb defines US river microbiomes at the genome level.

PacBio has announced their anticipated desktop HiFi sequencer, the Vega sequencing platform, something they’ve been talking about since early 2023. The platform, which is slated to ship in Q1 2025,…

PacBio announced their new SPRQ long read sequencing chemistry ahead of ASHG. While it improves a couple of things, the headline is that it brings down the cost of a long read HiFi human genome to …

It’s an exciting time in the sequencing industry. After years of dominance, Illumina started facing competition on all fronts in 2022. Element Biosciences and Singular Genomics launched their deskt…

A number of academic labs and startups have been trying to build new ways of parallel sequencing of large numbers of peptides using schemes ...